GlobeNewswire·Jul 28, 2026, 9:00 AM ET

Biotech Division of Greenland Mines Announces Issuance of Patent in Canada for the Klotho Gene Therapy Platform Technology for Alzheimer’s and Aging

Greenland Mines Ltd (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada granted Patent No. CA3,005,398 for a technology exclusively licensed from Universitat Autònoma de Barcelona.
The patent covers a human gene therapy using the nucleic acid sequence encoding the RNA splice variant protein secreted Klotho (s-KL) for worldwide commercialization.
The granted patent includes 42 claims protecting the synthesis of s-KL, delivery methods, and its utility in treating neurodegenerative diseases by restoring normal tissue Klotho levels.
Dr. Joseph Sinkule confirmed the patent protects the treatment of conditions including Alzheimer's, Parkinson's, Huntington's, ALS, Dementia, Multiple Sclerosis, and various forms of trauma-related dementia.
The company's product candidate KLTO-101 will begin process development and manufacturing in August 2026, following patents issued in the US, China, and Europe.
The second product candidate, KLTO-202 for ALS and other neuromuscular disorders, has advanced to the GMP manufacturing stage with FDA interactions planned before the end of 2026.
Greenland Mines operates two divisions: Mining, focused on the Skaergaard and Sarfartoq projects for rare earths, and Biotech, centered on Klotho-based therapeutic programs.